Free Trial

Beigene, Ltd. (NASDAQ:ONC) SVP Chan Henry Lee Sells 700 Shares

Beigene logo with Medical background

Beigene, Ltd. (NASDAQ:ONC - Get Free Report) SVP Chan Henry Lee sold 700 shares of the stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $256.11, for a total value of $179,277.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Beigene Trading Down 2.5%

ONC stock traded down $6.90 during mid-day trading on Friday, reaching $269.63. The company's stock had a trading volume of 391,727 shares, compared to its average volume of 451,056. The company has a market capitalization of $31.92 billion, a P/E ratio of -32.72, a price-to-earnings-growth ratio of 7.73 and a beta of 0.30. The business's 50 day moving average price is $240.18. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93. Beigene, Ltd. has a 12 month low of $141.31 and a 12 month high of $287.88.

Beigene (NASDAQ:ONC - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, beating the consensus estimate of ($0.71) by $1.93. The firm had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.12 billion. Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. As a group, equities analysts expect that Beigene, Ltd. will post -5.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. JPMorgan Chase & Co. increased their price target on Beigene from $311.00 to $317.00 and gave the company an "overweight" rating in a research note on Monday, April 21st. Royal Bank of Canada reduced their target price on Beigene from $312.00 to $311.00 and set an "outperform" rating on the stock in a report on Thursday, May 8th. Guggenheim raised their price objective on Beigene from $348.00 to $350.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Bank of America raised Beigene from a "neutral" rating to a "buy" rating and lifted their price target for the company from $207.00 to $320.00 in a research note on Monday, March 3rd. Finally, Macquarie lifted their price target on Beigene from $259.00 to $313.00 and gave the company an "outperform" rating in a research note on Friday, February 28th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Beigene has an average rating of "Buy" and an average price target of $319.00.

View Our Latest Stock Analysis on Beigene

Beigene Company Profile

(Get Free Report)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

Further Reading

Insider Buying and Selling by Quarter for Beigene (NASDAQ:ONC)

Should You Invest $1,000 in BeOne Medicines Right Now?

Before you consider BeOne Medicines, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.

While BeOne Medicines currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

2 Chip Stocks Are Soaring—But One Could Break Out This Summer
Congress Bought This Stock at the Bottom—Will You Miss It?
These 3 Penny Stocks Could Surprise Everyone This Summer!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines